Mirum Pharmaceuticals (MIRM)
NASDAQ:MIRM
Want to see MIRM full AI Analyst Report?
MIRM Stock Chart & Stats
$97.95
-$0.27(-0.64%)
At close: 4:00 PM EST
$97.95
-$0.27(-0.64%)
Day’s Range― - ―
52-Week Range$43.50 - $114.99
Previous CloseN/A
Volume92.82K
Average Volume (3M)1.08M
Market Cap
$5.62B
Enterprise Value$5.09B
Total Cash (Recent Filing)$386.26M
Total Debt (Recent Filing)$323.78M
Price to Earnings (P/E)―
Beta0.79
Next Earnings
Jul 30, 2026EPS Estimate
-0.74Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-13.61
Shares Outstanding60,981,228
10 Day Avg. Volume920,651
30 Day Avg. Volume1,083,853
Financial Highlights & Ratios
PEG Ratio2.28
Price to Book (P/B)12.60
Price to Sales (P/S)7.61
P/FCF Ratio72.26
Enterprise Value/Market Cap0.91
Enterprise Value/Revenue8.94
Enterprise Value/Gross Profit10.99
Enterprise Value/Ebitda-132.89
Forecast
1Y Price Target
$144.54Price Target Upside47.56% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)-15.49
Revenue Forecast (FY)$674.60M
Bulls Say, Bears Say
Bulls Say
Sustained Revenue Growth & Upward GuidanceConsistent multi-year top-line expansion and a material upward guidance revision signal durable commercial traction for Mirum’s marketed medicines. Strong demand and improving penetration across U.S. and international channels support repeatable revenue conversion and reduce execution risk over the next 2–6 months.
Robust Product-Level EconomicsMid-50% cash contribution margins indicate high incremental profitability per unit sold, enabling scalable gross-margin leverage as sales grow. Durable unit economics support reinvestment in salesforce expansion and R&D while improving the path to sustained operating cash generation as volumes rise.
Pipeline & BD Progress Diversifies GrowthRecent BD and positive mid-stage readouts (volixibat, brelovitug) materially broaden Mirum’s addressable liver-disease markets beyond pediatric PFIC. Near-term regulatory catalysts and potential year-end launches create durable optionality to expand revenues and reduce single-product concentration risk if approvals succeed.
Bears Say
Increased Financial LeverageHigher debt-to-equity reduces financial flexibility and raises refinancing and covenant risk if operating losses persist. Elevated leverage constrains the company's ability to fund opportunistic investments or weather slower sales, increasing the importance of consistent cash generation over the coming months.
Renewed Trailing Cash Burn & Volatile Cash FlowA reversion to negative TTM operating and free cash flow signals renewed funding pressure; volatile cash generation undermines self-funding and raises dependence on external financing. If sustained, this elevates dilution and liquidity risk during key clinical and commercial scaling periods.
Potential Dilution & Complex Convertible FinancingLarge, long-dated convertible issuance provides liquidity but carries conversion and anti-dilution mechanics that can increase share count or constrain strategic options. Structural dilution risk and creditor protections may weigh on per-share metrics and complicate capitalization as the company scales and seeks further financing.
Mirum Pharmaceuticals News
MIRM FAQ
What was Mirum Pharmaceuticals’s price range in the past 12 months?
Mirum Pharmaceuticals lowest stock price was $43.50 and its highest was $114.99 in the past 12 months.
What is Mirum Pharmaceuticals’s market cap?
Mirum Pharmaceuticals’s market cap is $5.62B.
When is Mirum Pharmaceuticals’s upcoming earnings report date?
Mirum Pharmaceuticals’s upcoming earnings report date is Jul 30, 2026 which is in 57 days.
How were Mirum Pharmaceuticals’s earnings last quarter?
Mirum Pharmaceuticals released its earnings results on May 06, 2026. The company reported -$13.43 earnings per share for the quarter, missing the consensus estimate of -$0.365 by -$13.065.
Is Mirum Pharmaceuticals overvalued?
According to Wall Street analysts Mirum Pharmaceuticals’s price is currently Undervalued.
Does Mirum Pharmaceuticals pay dividends?
Mirum Pharmaceuticals does not currently pay dividends.
What is Mirum Pharmaceuticals’s EPS estimate?
Mirum Pharmaceuticals’s EPS estimate is -0.74.
How many shares outstanding does Mirum Pharmaceuticals have?
Mirum Pharmaceuticals has 60,981,228 shares outstanding.
What happened to Mirum Pharmaceuticals’s price movement after its last earnings report?
Mirum Pharmaceuticals reported an EPS of -$13.43 in its last earnings report, missing expectations of -$0.365. Following the earnings report the stock price went down -6.495%.
Which hedge fund is a major shareholder of Mirum Pharmaceuticals?
Currently, no hedge funds are holding shares in MIRM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Mirum Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$144.54 (47.56% Upside)
$144.54 (47.56% Upside)
Blogger Sentiment
Bullish
MIRM Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 576.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.6%
Last 30 Days ▲ 7.9%
Last 30 Days ▲ 7.9%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
100.50%
12-Months-Change
Fundamentals
Return on Equity
-289.33%
Trailing 12-Months
Asset Growth
29.07%
Trailing 12-Months
Company Description
Mirum Pharmaceuticals
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.
MIRM Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented strong commercial momentum and meaningful pipeline and BD progress: solid Q1 sales growth (~42.9% YoY), an upward revision to full-year guidance, funded R&D investments, prioritized near-term regulatory catalysts (including a PDUFA on September 26, 2026), and a plan to scale the commercial team. These positives are tempered by a very large, one-time operating expense tied to the Bluejay acquisition that drove an unusually high quarterly operating charge ($761M of $949M), minimal Q1 operating cash flow (~$2M), elevated R&D spend, and remaining data and market-size uncertainties for some pipeline assets (e.g., FOP patient counts and certain subgroup signals in hepatitis delta). Management expects operating cash flow positivity next year and GAAP profitability by 2028, indicating confidence in the business model despite near-term accounting and investment-driven headwinds.View all MIRM earnings summariesMIRM Stock 12 Month Forecast
Average Price Target
$144.54
▲(47.56% Upside)
Technical Analysis
Arrowhead Pharmaceuticals
―
Catalyst Pharma
―
Ultragenyx Pharmaceutical
―
ImmunityBio
―
―
Ownership Overview
7.97% Insiders
29.27% Mutual Funds
48.40% Other Institutional Investors
1.30% Public Companies and
Individual Investors